Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA-HER1
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
SNA-HER1 is a micro-immunotherapy medicinal product developed by Labo'Life, specifically designed for the management of infections caused by Herpes Simplex Virus type 1 (HSV-1), such as orofacial herpes (cold sores). The SNA designation stands for Specific Nucleic Acids, which are low-dose (micro-dose) synthetic oligonucleotides designed to be complementary to essential regions of the viral genome. The mechanism of action involves the inhibition of viral replication through an antisense-like effect, aimed at reducing viral load and the frequency of symptomatic outbreaks. As part of the micro-immunotherapy framework, SNA-HER1 is intended to modulate the immune system's response to the virus rather than providing a direct high-dose antiviral effect. It is typically administered sublingually in the form of granules to facilitate absorption through the oral mucosa.
- Brand names
- SNA-HER1SNA-HER-1SNA-HER 1
- Other names
- Specific Nucleic Acid HER1
Beyond the preview
Go deeper on SNA-HER1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA-HER1.